Nuwellis, Inc. ( (NUWE) ) has released its Q1 earnings. Here is a breakdown of the information Nuwellis, Inc. presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Nuwellis, Inc. is a commercial-stage medical device company focused on transforming care for patients with fluid overload through its Aquadex SmartFlow system. The company operates primarily in the healthcare sector, with a unique emphasis on ultrafiltration therapy for both adult and pediatric patients.
In its first quarter of 2025, Nuwellis reported a modest revenue increase of 3% year-over-year, reaching $1.9 million. The company highlighted significant growth in its pediatric segment and a strategic focus on expanding outpatient opportunities, supported by favorable changes in reimbursement policies.
Key financial metrics from the quarter include a 4% rise in consumables utilization and a 38% increase in pediatric revenue. The company also achieved a 31% reduction in operating expenses, contributing to an improved operating loss of $3.1 million compared to the previous year’s $4.7 million. However, the gross margin decreased to 56% from 64.1%, attributed to unfavorable manufacturing variances and inventory adjustments.
Looking ahead, Nuwellis is optimistic about expanding the adoption of its Aquadex therapy, particularly in outpatient settings, bolstered by higher reimbursement rates and growing clinical support. The company remains focused on strategic growth and operational efficiency to enhance its market position in 2025.